Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Satellite observations offer insight into a tsunami's early stages - 2Stolen Renoir, Cézanne and Matisse were probably uninsured, market sources say
- 3France bans Muslim gathering citing risk to participants
- 4Two UN peacekeepers killed in explosion in Lebanon
- 5'Stranger Things' made him a heartthrob. He left Hollywood anyway.
- EU delays signing of Mercosur free trade deal
- Native artists in Texas and Mexico shared their vision of the universe for 4,000 years, ancient murals suggest
- Green Inflections: A Manual for Inside Plants
- ‘Harry Potter and the Philosopher’s Stone’ trailer is raising eyebrows among Potterheads: ‘Where’s the whimsical color?’
- The most effective method to Execute a Lung-Solid Eating routine After a Cellular breakdown in the lungs Finding
- 'Something Very Bad Is Going to Happen' is the Duffer Brothers' first project since 'Stranger Things.' It's also 'wildly insane.'
- Step by step instructions to Explore Assessment Ramifications of Disc Rates
- 5 Worldwide Road Food varieties You Should Attempt
- Ancient fire discovery marks significant milestone in human history
